AbbVie and Boehringer Ingelheim GmbH resolved all ongoing intellectual property litigation regarding BI's Cyltezo adalimumabadbm a biosimilar to AbbVie's Humira adalimumab. Cyltezo was FDA approved in August 2017 for chronic inflammatory diseases including...
↧